Overview

Bupivacaine Supplementation For Postoperative Pain Control In Surgical Removal Of Mandibular Third Molars

Status:
Unknown status
Trial end date:
2015-07-01
Target enrollment:
0
Participant gender:
All
Summary
Control of postoperative pain is a foremost goal in achieving a satisfactory postoperative recovery. Surgical removal of lower third molars is accompanied by postoperative pain that is at its peak in the first 12 hours. Our study evaluates if the use of 2% lidocaine hydrochloride for the surgical removal of lower third molars with a postoperative 0.5% bupivacaine supplementation would result in lesser postoperative pain and a decrease in ingestion of oral analgesics to control the pain when compared to a placebo.
Phase:
N/A
Accepts Healthy Volunteers?
Accepts Healthy Volunteers
Details
Lead Sponsor:
Cosmozone Dental Clinic
Treatments:
Bupivacaine
Pharmaceutical Solutions
Criteria
Inclusion Criteria:

- healthy ASA [American Society of Anaesthesiologists] class 1 patients with mandibular
bilateral, symmetrical, impacted third molars indicated for extraction.

Exclusion Criteria:

- unilateral impacted and bilateral asymmetrical impacted molars;

- those who misused alcohol, had chronic pain,

- those who took narcotic drugs, beta-blockers, or any analgesic drug within 24 hours
before the operation

- those with known hypersensitivity to amide types of local anesthetics.